1. A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX.
- Author
-
Jamison JK, May MS, Raufi AG, Luk L, Wong W, Mundi PS, and Manji GA
- Subjects
- Humans, Antineoplastic Combined Chemotherapy Protocols therapeutic use, BRCA2 Protein genetics, BRCA1 Protein genetics, Irinotecan, Oxaliplatin, Leucovorin, Fluorouracil, Adenocarcinoma drug therapy, Adenocarcinoma genetics, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms genetics, Cancer Survivors
- Abstract
Homologous recombination repair (HRR) pathway deficiency opens multiple therapeutic avenues within pancreatic cancer. Patients with HRR deficiency-associated gene mutations such as BRCA1, BRCA2, and PALB2 are more susceptible to platinum-based chemotherapies and in those with somatic BRCA mutations, PARP inhibitor therapy prolongs progression-free survival. The case discussed herein illustrates the therapeutic opportunities offered through the identification of HRR deficiency in pancreatic cancer, as well as the challenges associated with treatment and prevention of central nervous system metastases in long-term survivors of pancreatic cancer., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF